| Code | CSB-RA865099MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to the DCSZ-11 reference antibody, targeting CD93 (also known as C1qRp or complement component C1q receptor). CD93 is a type I transmembrane glycoprotein expressed on endothelial cells, hematopoietic stem cells, and certain myeloid cell populations. This receptor plays crucial roles in cell adhesion, migration, and phagocytosis of apoptotic cells, while also participating in complement-mediated immune responses. CD93 expression has been implicated in various pathological conditions, including inflammatory disorders, cardiovascular diseases, and cancer, where it influences angiogenesis, tumor progression, and immune cell trafficking.
The DCSZ-11 antibody has been established as a valuable research tool for investigating CD93 expression patterns and functional mechanisms in both normal physiology and disease contexts. This biosimilar provides researchers with a reliable reagent for studying CD93-mediated cellular processes, examining its role in immune regulation, and exploring potential therapeutic targeting strategies in oncology and inflammatory disease research. The antibody enables detailed investigation of CD93 biology across multiple experimental systems.
There are currently no reviews for this product.